Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults

Share this article:
Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults
Acute Myeloid Leukemia Risk Factors ID'd in Texas Adults

(HealthDay News) -- Solvent exposure, smoking, and obesity are significant risk factors for de novo acute myeloid leukemia (AML) in Texas, according to a study published online Feb. 1 in Cancer.

To investigate associations between lifestyle characteristics and AML risk, Sara S. Strom, Ph.D., of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues used questionnaires to collect demographic and occupational characteristics on 638 adults with de novo AML and 636 matched controls.

The researchers found that AML risk was significantly increased among men exposed to low or moderate/high levels of occupational solvents (odds ratio [OR], 2.87 and 4.13, respectively), or men who were heavy smokers (≥30 pack-years; OR, 1.86). For women, there was a significantly increased risk of AML with exposure to low or moderate/high levels of solvent (OR, 2.73 and 3.90, respectively), or for those who were obese (OR 1.62). Obesity correlated with a significantly increased risk of AML with recurrent cytogenetic abnormalities (RCA) (OR, 3.15). Solvent exposure at low or moderate/high levels correlated with a significantly increased risk of AML-RCA or AML with multilineage dysplasia (low level OR, 4.11 and 2.54, respectively, and moderate/high level OR, 5.13 and 3.02, respectively). There was a joint effect of smoking and solvent exposure, with the highest risk seen for smokers who were exposed to solvents (OR, 4.51).

"These findings highlight the need for multicenter collaborations to identify the epidemiologic and genetic risk factors associated with AML development to better understand the complexity of AML etiology and the underlying heterogeneity of the disease," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.

Adherence rates for prostate cancer quality of care measures low

Adherence rates for prostate cancer quality of care ...

Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation.